Abstract:Background Epstein Barr virus (EBV) is a highly prevalent herpesvirus worldwide and its infection is associated with malignancies such as nasopharyngeal cancer (NPC), gastric cancer, lymphoepithelioma cancer and lymphoproliferative disorders. Virus-specific T (VST) cell therapies using T cells reactive against EBV have shown limited efficacy in clinical trials with several practical limitations such as the long preparation period and the variations of pre-existing EBV-reactive T cells in different donors. To overcome these technical constraints of the VST approach, we have established the genetically engineered T cells targeting EBV antigens with lentiviral transduction. A proof-of-concept clinical validation was further conducted against EBV+ malignancies (trial No. ChiCTR2100044497). Methods T cells were activated by CD3/CD28 stimulation, lentivirally transduced with codon-optimized CAR (targeting EBV envelope protein) or TCR (targeting EBV latent membrane protein) and further expanded ex vivo. Transgene expression and the T cell phenotype were assessed by flow cytometry. In vitro anti-tumor efficacy was analyzed by IFN-γ ELISA and killing assays such as RTCA Xcelligence. In vivo, the antitumor efficacy of EBV-specific T cells was evaluated in immunocompromised mice bearing human tumor xenografts. Anti-tumor responses in lymphoma and NPC were evaluated by Lugano 2014 and RECIST 1.1 respectively. Results T cells lentivirally transduced with EBV antigen-specific CAR or TCR demonstrated satisfactory surface expression of the introduced receptor and showed increased cytokine production when stimulated to target expressing tumor cells in vitro (figure 1). We have identified the TCRs against EBV latent membrane protein with high functional avidity as determined by peptide dose-response functional assays. In vitro cytotoxicity assays demonstrated strong killing of antigen positive tumor cell lines of the engineered EBV-specific CAR-T or TCR-T cells, while sparing the antigen-negative cells, indicating the specific T cell response. The single intravenous infusion of engineered EBV-specific T cells also led to dose-dependent anti-tumor responses in immunocompromised mouse xenograft models (figure 1). In the clinical trial, two patients with lymphoproliferative disease and one patient with advanced NPC treated with engineered EBV-targeting T cells experienced sustained objective responses. Moreover, in the NPC patient, the EBV DNA copy number decreased from 3.32*103 copies/ml at baseline to normal (<5.00*102 copies/ml) 2 months post infusion. The infused cells also demonstrated satisfactory safety profile with no neurotoxicity and ≥ Grade 2 cytokine release syndrome observed. Conclusions Our data demonstrate the feasibility of using genetically engineered T cells targeting EBV antigens such as envelope protein or latent membrane protein to treat EBV-associated malignancies. Trial Registration Chinese Clinical Trial Registry: ChiCTR2100044497 Ethics Approval All animal studies were conducted at Guangzhou Regenerative Medicine and Health, Guangdong Laboratory as approved by IACUC (2020125). The clinical study was approved by the first affiliated hospital of Zhengzhou University's Ethics Board (L2021-Y027–005).

Establishment of a protocol for rapidly expanding Epstein-Barr-virus-specific cytotoxic T cells with enhanced cytotoxicity

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

Anti-nasopharyngeal carcinoma effect in vivo and in vitro of cytotoxicity T lymphocyte induced by Ad5-latent membrane protein 2A]

LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders

EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation

Ex Vivo Expansion of Tumor-Infiltrating Lymphocytes from Nasopharyngeal Carcinoma Patients for Adoptive Immunotherapy.

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease

328 Preclinical Analyses and Proof of Concept Clinical Study of Epstein Barr Virus (EBV) Specific Genetically Modified T Cells Against EBV Associated Malignancies

Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.

Induction of the Epstein-Barr Virus Latent Membrane Protein 2 Antigen-specific Cytotoxic T Lymphocytes Using Human Leukocyte Antigen Tetramer-based Artificial Antigen-presenting Cells

Evaluation of Epstein-Barr Virus Latent Membrane Protein 2 Specific T-Cell Receptors Driven by T-Cell Specific Promoters Using Lentiviral Vector

The Efficacy and Safety of Epstein‐Barr Virus‐specific Antigen Peptide‐activated Cytotoxic T‐cells Treatment for Refractory or Recurrent Angioimmunoblastic T‐cell Lymphoma: A Prospective Clinical Observational Study

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

Optimizing the Conditions for in Vitro Expansion of HBV Protein Epitope-Specific CTLs

EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules

A Novel High Throughput Assay to Quantify Epstein-Barr Virus Neutralizing Antibody Activity Against B-cell and Epithelial Cell Infections for Vaccine and Therapeutic Developments.

Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas

In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus

Epstein‒Barr virus-associated cellular immunotherapy

EBV Promotes Human CD8 NKT Cell Development.

Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation